Terry Lain
Behavioral Neurology & Neuropsychiatry · New Orleans, LANPI 1295751006
Payments from drug & device makers
Across 153 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$420
- AbbVie$411
- Indivior Inc.$367
- Vanda Pharmaceuticals Inc.$306
- Takeda Pharmaceuticals U.S.A., Inc.$252
- Lundbeck LLC$196
- plus $867 from 11 others
What the payments were for
- Food & beverage$2,76598%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $420 |
| AbbVie | 36 | $411 |
| Indivior Inc. | 14 | $367 |
| Vanda Pharmaceuticals Inc. | 12 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $252 |
| Lundbeck LLC | 12 | $196 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $164 |
| Johnson & Johnson | 8 | $161 |
| Teva Pharmaceuticals USA, Inc. | 7 | $156 |
| Alkermes, Inc. | 7 | $121 |
| E.r. Squibb & Sons, L.L.C. | 2 | $71 |
| Orexo US, Inc. | 1 | $70 |
| Corium, LLC | 3 | $56 |
| Eisai Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $13 |
How this compares
Too few behavioral neurology & neuropsychiatry providers in Louisianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 32 | $91,968 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $18,996 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 67 | $18,496 |
| AmbienZolpidem Tartrate | 11 | $10,216 |
| Haloperidol | 38 | $1,766 |
| Divalproex Sodium ErDivalproex Sodium | 48 | $1,428 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $1,293 |
| Naloxone Hcl | 12 | $1,027 |
| Oxcarbazepine | 22 | $1,016 |
| Paliperidone ErPaliperidone | 13 | $979 |
| Clozapine | 12 | $893 |
| Bupropion XlBupropion Hcl | 62 | $630 |
| Doxepin Hcl | 13 | $550 |
| Quetiapine Fumarate | 63 | $486 |
| Aripiprazole | 24 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $161 | $91,96832 claims |
| Indivior Inc.Suboxone | $367 | $18,99624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in New Orleans
- Katherine SmithNew Orleans$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.